Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.82 Million EUR | -112.14% |
| 2022 | 44.07 Million EUR | -52.33% |
| 2021 | 92.44 Million EUR | -40.72% |
| 2020 | 155.94 Million EUR | 991.82% |
| 2019 | -17.48 Million EUR | -24.26% |
| 2018 | -14.07 Million EUR | 20.41% |
| 2017 | -17.68 Million EUR | 5.48% |
| 2016 | -18.7 Million EUR | -265.12% |
| 2015 | 11.32 Million EUR | -44.02% |
| 2014 | 20.23 Million EUR | 6.76% |
| 2013 | 18.95 Million EUR | 30.13% |
| 2012 | 14.56 Million EUR | 106.16% |
| 2011 | 7.06 Million EUR | 174.25% |
| 2010 | -9.51 Million EUR | 70.51% |
| 2009 | -32.27 Million EUR | 12.91% |
| 2008 | -37.05 Million EUR | 18.26% |
| 2007 | -45.33 Million EUR | 5.59% |
| 2006 | -48.01 Million EUR | -471.78% |
| 2005 | -8.39 Million EUR | 3.49% |
| 2004 | -8.7 Million EUR | 68.63% |
| 2003 | -27.73 Million EUR | 37.39% |
| 2002 | -44.3 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.93 Million EUR | 4.64% |
| 2024 Q3 | 5.48 Million EUR | 850.82% |
| 2024 Q2 | -730 Thousand EUR | 85.21% |
| 2023 FY | -5.35 Million EUR | -112.14% |
| 2023 Q4 | -5.17 Million EUR | -2713.04% |
| 2023 Q3 | -184 Thousand EUR | -104.55% |
| 2023 Q2 | 4.04 Million EUR | 257.35% |
| 2023 Q1 | -2.57 Million EUR | -176.28% |
| 2022 FY | 44.07 Million EUR | -52.33% |
| 2022 Q1 | 19.01 Million EUR | -56.15% |
| 2022 Q2 | 9.83 Million EUR | -48.3% |
| 2022 Q4 | 3.37 Million EUR | -71.56% |
| 2022 Q3 | 11.85 Million EUR | 20.6% |
| 2021 Q3 | 49.04 Million EUR | 371.46% |
| 2021 FY | 92.44 Million EUR | -40.72% |
| 2021 Q1 | 18.1 Million EUR | -3.21% |
| 2021 Q2 | -18.06 Million EUR | -199.79% |
| 2021 Q4 | 43.36 Million EUR | -11.59% |
| 2020 FY | 155.94 Million EUR | 991.82% |
| 2020 Q1 | 70.5 Million EUR | 296.73% |
| 2020 Q3 | 22.21 Million EUR | -50.11% |
| 2020 Q4 | 18.7 Million EUR | -15.79% |
| 2020 Q2 | 44.52 Million EUR | -36.84% |
| 2019 Q2 | -4.55 Million EUR | 50.02% |
| 2019 Q4 | -35.83 Million EUR | -211.89% |
| 2019 Q1 | -9.11 Million EUR | 15.02% |
| 2019 Q3 | 32.02 Million EUR | 802.65% |
| 2019 FY | -17.48 Million EUR | -24.26% |
| 2018 Q1 | -2.74 Million EUR | 63.99% |
| 2018 Q4 | -10.73 Million EUR | -61.78% |
| 2018 Q2 | 6.03 Million EUR | 319.88% |
| 2018 Q3 | -6.63 Million EUR | -209.85% |
| 2018 FY | -14.07 Million EUR | 20.41% |
| 2017 Q1 | -1.65 Million EUR | 78.08% |
| 2017 Q4 | -7.62 Million EUR | -33.79% |
| 2017 FY | -17.68 Million EUR | 5.48% |
| 2017 Q3 | -5.7 Million EUR | -110.88% |
| 2017 Q2 | -2.7 Million EUR | -63.62% |
| 2016 Q4 | -7.53 Million EUR | -291.53% |
| 2016 FY | -18.7 Million EUR | -265.12% |
| 2016 Q2 | -3.49 Million EUR | 39.29% |
| 2016 Q3 | -1.92 Million EUR | 44.87% |
| 2016 Q1 | -5.75 Million EUR | -1806.82% |
| 2015 Q1 | 7.96 Million EUR | 670.7% |
| 2015 FY | 11.32 Million EUR | -44.02% |
| 2015 Q4 | 337 Thousand EUR | -92.66% |
| 2015 Q3 | 4.59 Million EUR | 393.04% |
| 2015 Q2 | -1.56 Million EUR | -119.67% |
| 2014 Q4 | -1.39 Million EUR | -165.11% |
| 2014 FY | 20.23 Million EUR | 6.76% |
| 2014 Q3 | 2.14 Million EUR | 52.06% |
| 2014 Q2 | 1.41 Million EUR | -92.2% |
| 2014 Q1 | 18.07 Million EUR | 2639.24% |
| 2013 Q3 | 908 Thousand EUR | -2.47% |
| 2013 Q4 | 660 Thousand EUR | -27.31% |
| 2013 FY | 18.95 Million EUR | 30.13% |
| 2013 Q1 | 16.45 Million EUR | 580.5% |
| 2013 Q2 | 931 Thousand EUR | -94.34% |
| 2012 Q3 | -2.59 Million EUR | -114.48% |
| 2012 FY | 14.56 Million EUR | 106.16% |
| 2012 Q1 | -4.92 Million EUR | -126.09% |
| 2012 Q2 | 17.89 Million EUR | 463.05% |
| 2012 Q4 | -3.42 Million EUR | -32.19% |
| 2011 Q1 | -3.67 Million EUR | 53.82% |
| 2011 Q4 | 18.89 Million EUR | 592.83% |
| 2011 FY | 7.06 Million EUR | 174.25% |
| 2011 Q3 | -3.83 Million EUR | -17322.73% |
| 2011 Q2 | -22 Thousand EUR | 99.4% |
| 2010 Q1 | -1.09 Million EUR | 94.98% |
| 2010 Q2 | 514 Thousand EUR | 147.16% |
| 2010 FY | -9.51 Million EUR | 70.51% |
| 2010 Q3 | -974 Thousand EUR | -289.49% |
| 2010 Q4 | -7.96 Million EUR | -717.97% |
| 2009 Q3 | -6.21 Million EUR | -222.1% |
| 2009 Q1 | -2.41 Million EUR | 78.55% |
| 2009 Q2 | -1.92 Million EUR | 20.3% |
| 2009 FY | -32.27 Million EUR | 12.91% |
| 2009 Q4 | -21.71 Million EUR | -249.66% |
| 2008 Q4 | -11.27 Million EUR | 10.14% |
| 2008 Q3 | -12.54 Million EUR | -624.54% |
| 2008 Q2 | -1.73 Million EUR | 84.94% |
| 2008 Q1 | -11.49 Million EUR | 0.0% |
| 2008 FY | -37.05 Million EUR | 18.26% |
| 2007 FY | -45.33 Million EUR | 5.59% |
| 2006 FY | -48.01 Million EUR | -471.78% |
| 2005 FY | -8.39 Million EUR | 3.49% |
| 2004 FY | -8.7 Million EUR | 68.63% |
| 2003 FY | -27.73 Million EUR | 37.39% |
| 2002 FY | -44.3 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -0.179% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 94.669% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1362.216% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.953% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -34.257% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 78.557% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.676% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -149.146% |
| Marizyme, Inc. | -34.08 Million USD | 88.773% |
| Genus plc | 6.4 Million USD | 159.797% |
| Pharming Group N.V. | -4.87 Million USD | 21.571% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -92.652% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -310.896% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 54.168% |
| ContraFect Corporation | -56.88 Million USD | 93.273% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -172.969% |
| IMV Inc. | -38.67 Million USD | 90.104% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -39.121% |
| ONE Bio Corp. | 13.68 Million USD | 127.972% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 93.512% |
| Mesoblast Limited | -84.14 Million USD | 95.452% |
| MultiCell Technologies, Inc. | -722.81 USD | -529361.408% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 208.107% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.08% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -882.365% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -45.651% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 177.867% |
| Biomind Labs Inc. | -1 Million USD | -279.06% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -31.909% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 42.434% |
| Skye Bioscience, Inc. | -13.67 Million USD | 72.008% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -105.27% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 139.282% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -12677.11% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 15.977% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 24.135% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 75.885% |
| Accustem Sciences Inc. | -3.74 Million USD | -2.151% |
| EV Biologics, Inc. | -483.06 Thousand USD | -692.238% |
| Q BioMed Inc. | -3.44 Million USD | -11.069% |
| GB Sciences, Inc. | -1.42 Million USD | -169.41% |
| Alpha Cognition Inc. | -9.7 Million USD | 60.569% |
| CSL Limited | 3.7 Billion USD | 100.103% |
| Agentix Corp. | -1.37 Million USD | -178.985% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.038% |
| Enzolytics Inc. | -2.14 Million USD | -78.099% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 69.982% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -20.791% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -98.022% |
| argenx SE | -425.04 Million USD | 99.1% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.105% |
| HST Global, Inc. | -140.9 Thousand USD | -2615.976% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -266.571% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -240.206% |
| Halberd Corporation | -75.05 Thousand USD | -4999.267% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -31.087% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -12.394% |
| Zenith Capital Corp. | -8.94 Million USD | 57.207% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -142.314% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -55.866% |
| AVAX Technologies, Inc. | 6.69 Million USD | 157.18% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2131.363% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -90.896% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -21867.74% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -55.143% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -288.902% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -204.697% |
| Kadimastem Ltd | -3.04 Million USD | -25.878% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 50.803% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2008.714% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -186.574% |
| LadRx Corporation | -3.82 Million USD | -0.088% |
| Cell Source, Inc. | -4.32 Million USD | 11.522% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -821.106% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -457.1% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -457.1% |
| Affymax, Inc. | -15.04 Million USD | 74.565% |
| Mobile Lads Corp. | -554.55 Thousand USD | -590.109% |
| Itoco Inc. | -919.14 Thousand USD | -316.367% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 9.707% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -242.002% |
| International Stem Cell Corporation | -663 Thousand USD | -477.225% |
| CytoDyn Inc. | -18.05 Million USD | 78.807% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -15104.609% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1638.929% |
| Qrons Inc. | -643.67 Thousand USD | -494.553% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -577.677% |
| SYBLEU INC | -149.18 Thousand USD | -2465.357% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -71.624% |
| Rebus Holdings, Inc. | -664 Thousand USD | -476.355% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -110.701% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7170.137% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -18715.143% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 89.447% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -136.527% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -420.089% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -23.015% |
| Neutra Corp. | -229.48 Thousand USD | -1567.64% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 78.18% |
| PureTech Health plc | -146.19 Million USD | 97.382% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 82.193% |
| IXICO plc | -1.43 Million USD | -166.319% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 59.678% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.858% |
| CSL Limited | 3.81 Billion USD | 100.1% |
| Cellectis S.A. | -108.85 Million USD | 96.484% |